Analysts cut PODD’s target to USD 220 from USD 280, citing stretched valuation metrics relative to peers.
Bernstein reduced Insulet’s stock price target to USD 220 from USD 280, reflecting concerns over elevated valuation levels. The firm maintained its market-perform rating on the medical device maker’s shares.
Insulet’s valuation has outpaced sector peers, prompting the downward revision despite strong revenue growth. The prior target of USD 280 was set in early 2024, before recent market volatility impacted healthcare stocks.
Shares of PODD traded slightly lower in pre-market activity following the note, though broader sector trends also weighed on sentiment.